STOCK TITAN

[8-K] Primis Financial Corp. Reports Material Event

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

BioSig Technologies (BSGM) has called a virtual special meeting to seek shareholder approval for several highly dilutive and governance-altering actions tied to its recently closed acquisition of Streamex Exchange Corp.

  • Proposal 1: Ratify issuance of ≈109.1 million common shares (plus one Super Voting Preferred share) to Streamex sellers. If approved, Streamex holders would ultimately control 75% of BioSig’s fully-diluted equity; existing investors fall to 25%.
  • Proposal 2: Authorize stock underlying convertible debentures to YA II PN, Ltd.
  • Proposal 3: Add 10,359,211 shares to the 2023 LTIP (total 14,735,806).
  • Proposal 4: Permit issuance of ≥19.99% of outstanding shares under a Standby Equity Purchase Agreement (SEPA) with Yorkville.
  • Proposal 5: Increase authorized common shares from 200 million to 500 million.
  • Proposal 6: Stagger the board into three classes.

The board unanimously recommends voting “FOR” all proposals. Quorum is one-third of voting power; most items need simple majority of votes cast, but the classified board requires majority of all outstanding shares. Risk disclosure highlights extensive dilution, regulatory uncertainty around Streamex’s gold-tokenization model, and integration challenges. Record date and meeting date remain blank pending SEC clearance.

BioSig Technologies (BSGM) ha convocato un'assemblea speciale virtuale per ottenere l'approvazione degli azionisti su diverse azioni altamente diluitive e modifiche di governance legate alla recente acquisizione di Streamex Exchange Corp.

  • Proposta 1: Ratificare l'emissione di circa 109,1 milioni di azioni ordinarie (più una azione preferenziale Super Voting) ai venditori di Streamex. Se approvata, i detentori di Streamex controlleranno il 75% del capitale azionario completamente diluito di BioSig; gli investitori attuali scenderanno al 25%.
  • Proposta 2: Autorizzare le azioni sottostanti ai debentures convertibili a favore di YA II PN, Ltd.
  • Proposta 3: Aggiungere 10.359.211 azioni al LTIP 2023 (totale 14.735.806).
  • Proposta 4: Consentire l'emissione di ≥19,99% delle azioni in circolazione nell'ambito di un Accordo di Acquisto Azionario Standby (SEPA) con Yorkville.
  • Proposta 5: Aumentare le azioni ordinarie autorizzate da 200 milioni a 500 milioni.
  • Proposta 6: Suddividere il consiglio di amministrazione in tre classi.

Il consiglio raccomanda all'unanimità di votare “A FAVORE” di tutte le proposte. Il quorum è un terzo del potere di voto; la maggior parte delle proposte richiede la maggioranza semplice dei voti espressi, mentre per il consiglio classificato è necessaria la maggioranza di tutte le azioni in circolazione. La comunicazione sui rischi evidenzia una diluizione significativa, incertezze normative riguardo al modello di tokenizzazione dell’oro di Streamex e sfide di integrazione. Le date di registrazione e dell'assemblea sono in attesa di approvazione dalla SEC.

BioSig Technologies (BSGM) ha convocado una reunión especial virtual para solicitar la aprobación de los accionistas sobre varias acciones altamente dilutivas y cambios en la gobernanza relacionados con su reciente adquisición de Streamex Exchange Corp.

  • Propuesta 1: Ratificar la emisión de aproximadamente 109,1 millones de acciones comunes (más una acción preferente con voto súper) a los vendedores de Streamex. Si se aprueba, los titulares de Streamex controlarían finalmente el 75% del capital totalmente diluido de BioSig; los inversores actuales caerían al 25%.
  • Propuesta 2: Autorizar las acciones subyacentes a los bonos convertibles para YA II PN, Ltd.
  • Propuesta 3: Añadir 10.359.211 acciones al LTIP 2023 (total 14.735.806).
  • Propuesta 4: Permitir la emisión de ≥19,99% de las acciones en circulación bajo un Acuerdo de Compra de Acciones en Espera (SEPA) con Yorkville.
  • Propuesta 5: Incrementar las acciones comunes autorizadas de 200 millones a 500 millones.
  • Propuesta 6: Dividir la junta directiva en tres clases.

La junta recomienda por unanimidad votar “A FAVOR” de todas las propuestas. El quórum es un tercio del poder de voto; la mayoría de los puntos requieren mayoría simple de los votos emitidos, pero la junta clasificada requiere mayoría de todas las acciones en circulación. La divulgación de riesgos destaca una dilución extensa, incertidumbre regulatoria sobre el modelo de tokenización de oro de Streamex y desafíos de integración. Las fechas de registro y de la reunión están pendientes de la aprobación de la SEC.

BioSig Technologies (BSGM)는 최근 완료된 Streamex Exchange Corp. 인수와 관련된 여러 고희석 및 지배구조 변경 사항에 대해 주주 승인을 받기 위해 가상 특별 회의를 소집했습니다.

  • 제안 1: Streamex 판매자에게 약 1억 9백만 주의 보통주(슈퍼 투표권 우선주 1주 포함) 발행을 비준합니다. 승인 시 Streamex 보유자는 BioSig의 완전 희석 주식의 75%를 최종적으로 통제하게 되며 기존 투자자는 25%로 감소합니다.
  • 제안 2: YA II PN, Ltd.에 대한 전환 사채 기초 주식 발행을 승인합니다.
  • 제안 3: 2023년 장기 인센티브 계획(LTIP)에 10,359,211주 추가(총 14,735,806주).
  • 제안 4: Yorkville과의 대기 주식 매입 계약(SEPA)에 따라 발행 주식의 ≥19.99% 발행을 허용합니다.
  • 제안 5: 승인된 보통주 수를 2억 주에서 5억 주로 증가시킵니다.
  • 제안 6: 이사회를 3개 계층으로 나눕니다.

이사회는 만장일치로 모든 제안에 대해 “찬성” 투표를 권고합니다. 정족수는 의결권의 3분의 1이며, 대부분 항목은 투표된 과반수 찬성이 필요하지만, 계층화된 이사회는 전체 발행 주식의 과반수 찬성이 필요합니다. 위험 공시에는 광범위한 희석, Streamex의 금 토큰화 모델에 대한 규제 불확실성, 통합 과제가 강조되어 있습니다. 기록일과 회의 날짜는 SEC 승인 대기 중입니다.

BioSig Technologies (BSGM) a convoqué une assemblée spéciale virtuelle afin d'obtenir l'approbation des actionnaires pour plusieurs mesures très dilutives et modifiant la gouvernance liées à sa récente acquisition de Streamex Exchange Corp.

  • Proposition 1 : Ratifier l'émission d'environ 109,1 millions d'actions ordinaires (plus une action préférentielle à super droit de vote) aux vendeurs de Streamex. Si approuvé, les détenteurs de Streamex contrôleront finalement 75 % du capital entièrement dilué de BioSig ; les investisseurs existants tomberont à 25 %.
  • Proposition 2 : Autoriser les actions sous-jacentes aux obligations convertibles pour YA II PN, Ltd.
  • Proposition 3 : Ajouter 10 359 211 actions au LTIP 2023 (total 14 735 806).
  • Proposition 4 : Permettre l'émission de ≥19,99 % des actions en circulation dans le cadre d'un accord d'achat d'actions en attente (SEPA) avec Yorkville.
  • Proposition 5 : Augmenter le nombre d'actions ordinaires autorisées de 200 millions à 500 millions.
  • Proposition 6 : Échelonner le conseil d'administration en trois classes.

Le conseil recommande à l'unanimité de voter « POUR » toutes les propositions. Le quorum est d'un tiers du pouvoir de vote ; la plupart des points nécessitent une majorité simple des voix exprimées, mais le conseil classifié requiert la majorité de toutes les actions en circulation. La divulgation des risques souligne une dilution importante, une incertitude réglementaire autour du modèle de tokenisation de l’or de Streamex et des défis d’intégration. La date d’enregistrement et la date de la réunion restent à déterminer en attente de l’approbation de la SEC.

BioSig Technologies (BSGM) hat eine virtuelle außerordentliche Hauptversammlung einberufen, um die Zustimmung der Aktionäre zu mehreren stark verwässernden und governance-verändernden Maßnahmen im Zusammenhang mit der kürzlich abgeschlossenen Übernahme von Streamex Exchange Corp. einzuholen.

  • Vorschlag 1: Genehmigung der Ausgabe von ca. 109,1 Millionen Stammaktien (plus eine Super Voting Preferred Aktie) an die Verkäufer von Streamex. Bei Zustimmung würden die Streamex-Inhaber letztlich 75 % des vollständig verwässerten Eigenkapitals von BioSig kontrollieren; bestehende Investoren sinken auf 25 %.
  • Vorschlag 2: Autorisierung der Aktien, die den wandelbaren Schuldverschreibungen an YA II PN, Ltd. zugrunde liegen.
  • Vorschlag 3: Hinzufügung von 10.359.211 Aktien zum LTIP 2023 (insgesamt 14.735.806).
  • Vorschlag 4: Erlaubnis zur Ausgabe von ≥19,99 % der ausstehenden Aktien im Rahmen einer Standby Equity Purchase Agreement (SEPA) mit Yorkville.
  • Vorschlag 5: Erhöhung der genehmigten Stammaktien von 200 Millionen auf 500 Millionen.
  • Vorschlag 6: Staffelung des Vorstands in drei Klassen.

Der Vorstand empfiehlt einstimmig, allen Vorschlägen „ZUSTIMMEN“ zu stimmen. Das Quorum beträgt ein Drittel der Stimmrechte; die meisten Punkte erfordern eine einfache Mehrheit der abgegebenen Stimmen, aber für den gestaffelten Vorstand ist eine Mehrheit aller ausstehenden Aktien notwendig. Die Risikoaufklärung weist auf erhebliche Verwässerung, regulatorische Unsicherheiten bezüglich des Gold-Tokenisierungsmodells von Streamex und Integrationsherausforderungen hin. Das Stichtags- und Versammlungsdatum stehen noch aus und hängen von der Freigabe der SEC ab.

Positive
  • Diversification: Streamex acquisition adds a second operating segment focused on tokenized real-world assets, potentially expanding revenue sources.
  • Liquidity backstop: SEPA and Yorkville convertible debentures provide flexible financing options to fund integration and growth.
  • Plan expansion: Added LTIP shares may help attract and retain key talent needed to execute new strategy.
Negative
  • Severe dilution: Streamex holders will own up to 75% post-approval; authorized shares jump to 500 million.
  • Governance entrenchment: Creation of a classified board and one Super Voting Preferred share diminishes minority influence.
  • Regulatory uncertainty: Streamex’s gold-tokenization business faces untested securities and commodities oversight.
  • Financing overhang: Yorkville debentures and SEPA could introduce continuous selling pressure.
  • Execution risk: Integration of a start-up with going-concern doubts into a medical-device company adds complexity and operational strain.

Insights

TL;DR: Transaction delivers new business line but hands 75 % control to Streamex, triggers massive dilution, and relies on additional Yorkville financing.

The share issuance, SEPA and debentures could more than triple BioSig’s float, pressuring price and complicating future capital raises. While diversification into tokenized gold may expand TAM, the business is pre-revenue and faces heavy regulatory and liquidity risks. Increasing authorized shares to 500 million and adopting a classified board reduce shareholder leverage going forward. Net impact skews negative for current holders.

TL;DR: Proposals shift power from existing investors to new insiders and entrench the board.

The Super Voting Preferred share and staggered board limit accountability. Combined with Yorkville facilities, management gains latitude to issue large blocks without further approval. Shareholders must weigh potential growth against reduced influence and sustained dilution risk.

BioSig Technologies (BSGM) ha convocato un'assemblea speciale virtuale per ottenere l'approvazione degli azionisti su diverse azioni altamente diluitive e modifiche di governance legate alla recente acquisizione di Streamex Exchange Corp.

  • Proposta 1: Ratificare l'emissione di circa 109,1 milioni di azioni ordinarie (più una azione preferenziale Super Voting) ai venditori di Streamex. Se approvata, i detentori di Streamex controlleranno il 75% del capitale azionario completamente diluito di BioSig; gli investitori attuali scenderanno al 25%.
  • Proposta 2: Autorizzare le azioni sottostanti ai debentures convertibili a favore di YA II PN, Ltd.
  • Proposta 3: Aggiungere 10.359.211 azioni al LTIP 2023 (totale 14.735.806).
  • Proposta 4: Consentire l'emissione di ≥19,99% delle azioni in circolazione nell'ambito di un Accordo di Acquisto Azionario Standby (SEPA) con Yorkville.
  • Proposta 5: Aumentare le azioni ordinarie autorizzate da 200 milioni a 500 milioni.
  • Proposta 6: Suddividere il consiglio di amministrazione in tre classi.

Il consiglio raccomanda all'unanimità di votare “A FAVORE” di tutte le proposte. Il quorum è un terzo del potere di voto; la maggior parte delle proposte richiede la maggioranza semplice dei voti espressi, mentre per il consiglio classificato è necessaria la maggioranza di tutte le azioni in circolazione. La comunicazione sui rischi evidenzia una diluizione significativa, incertezze normative riguardo al modello di tokenizzazione dell’oro di Streamex e sfide di integrazione. Le date di registrazione e dell'assemblea sono in attesa di approvazione dalla SEC.

BioSig Technologies (BSGM) ha convocado una reunión especial virtual para solicitar la aprobación de los accionistas sobre varias acciones altamente dilutivas y cambios en la gobernanza relacionados con su reciente adquisición de Streamex Exchange Corp.

  • Propuesta 1: Ratificar la emisión de aproximadamente 109,1 millones de acciones comunes (más una acción preferente con voto súper) a los vendedores de Streamex. Si se aprueba, los titulares de Streamex controlarían finalmente el 75% del capital totalmente diluido de BioSig; los inversores actuales caerían al 25%.
  • Propuesta 2: Autorizar las acciones subyacentes a los bonos convertibles para YA II PN, Ltd.
  • Propuesta 3: Añadir 10.359.211 acciones al LTIP 2023 (total 14.735.806).
  • Propuesta 4: Permitir la emisión de ≥19,99% de las acciones en circulación bajo un Acuerdo de Compra de Acciones en Espera (SEPA) con Yorkville.
  • Propuesta 5: Incrementar las acciones comunes autorizadas de 200 millones a 500 millones.
  • Propuesta 6: Dividir la junta directiva en tres clases.

La junta recomienda por unanimidad votar “A FAVOR” de todas las propuestas. El quórum es un tercio del poder de voto; la mayoría de los puntos requieren mayoría simple de los votos emitidos, pero la junta clasificada requiere mayoría de todas las acciones en circulación. La divulgación de riesgos destaca una dilución extensa, incertidumbre regulatoria sobre el modelo de tokenización de oro de Streamex y desafíos de integración. Las fechas de registro y de la reunión están pendientes de la aprobación de la SEC.

BioSig Technologies (BSGM)는 최근 완료된 Streamex Exchange Corp. 인수와 관련된 여러 고희석 및 지배구조 변경 사항에 대해 주주 승인을 받기 위해 가상 특별 회의를 소집했습니다.

  • 제안 1: Streamex 판매자에게 약 1억 9백만 주의 보통주(슈퍼 투표권 우선주 1주 포함) 발행을 비준합니다. 승인 시 Streamex 보유자는 BioSig의 완전 희석 주식의 75%를 최종적으로 통제하게 되며 기존 투자자는 25%로 감소합니다.
  • 제안 2: YA II PN, Ltd.에 대한 전환 사채 기초 주식 발행을 승인합니다.
  • 제안 3: 2023년 장기 인센티브 계획(LTIP)에 10,359,211주 추가(총 14,735,806주).
  • 제안 4: Yorkville과의 대기 주식 매입 계약(SEPA)에 따라 발행 주식의 ≥19.99% 발행을 허용합니다.
  • 제안 5: 승인된 보통주 수를 2억 주에서 5억 주로 증가시킵니다.
  • 제안 6: 이사회를 3개 계층으로 나눕니다.

이사회는 만장일치로 모든 제안에 대해 “찬성” 투표를 권고합니다. 정족수는 의결권의 3분의 1이며, 대부분 항목은 투표된 과반수 찬성이 필요하지만, 계층화된 이사회는 전체 발행 주식의 과반수 찬성이 필요합니다. 위험 공시에는 광범위한 희석, Streamex의 금 토큰화 모델에 대한 규제 불확실성, 통합 과제가 강조되어 있습니다. 기록일과 회의 날짜는 SEC 승인 대기 중입니다.

BioSig Technologies (BSGM) a convoqué une assemblée spéciale virtuelle afin d'obtenir l'approbation des actionnaires pour plusieurs mesures très dilutives et modifiant la gouvernance liées à sa récente acquisition de Streamex Exchange Corp.

  • Proposition 1 : Ratifier l'émission d'environ 109,1 millions d'actions ordinaires (plus une action préférentielle à super droit de vote) aux vendeurs de Streamex. Si approuvé, les détenteurs de Streamex contrôleront finalement 75 % du capital entièrement dilué de BioSig ; les investisseurs existants tomberont à 25 %.
  • Proposition 2 : Autoriser les actions sous-jacentes aux obligations convertibles pour YA II PN, Ltd.
  • Proposition 3 : Ajouter 10 359 211 actions au LTIP 2023 (total 14 735 806).
  • Proposition 4 : Permettre l'émission de ≥19,99 % des actions en circulation dans le cadre d'un accord d'achat d'actions en attente (SEPA) avec Yorkville.
  • Proposition 5 : Augmenter le nombre d'actions ordinaires autorisées de 200 millions à 500 millions.
  • Proposition 6 : Échelonner le conseil d'administration en trois classes.

Le conseil recommande à l'unanimité de voter « POUR » toutes les propositions. Le quorum est d'un tiers du pouvoir de vote ; la plupart des points nécessitent une majorité simple des voix exprimées, mais le conseil classifié requiert la majorité de toutes les actions en circulation. La divulgation des risques souligne une dilution importante, une incertitude réglementaire autour du modèle de tokenisation de l’or de Streamex et des défis d’intégration. La date d’enregistrement et la date de la réunion restent à déterminer en attente de l’approbation de la SEC.

BioSig Technologies (BSGM) hat eine virtuelle außerordentliche Hauptversammlung einberufen, um die Zustimmung der Aktionäre zu mehreren stark verwässernden und governance-verändernden Maßnahmen im Zusammenhang mit der kürzlich abgeschlossenen Übernahme von Streamex Exchange Corp. einzuholen.

  • Vorschlag 1: Genehmigung der Ausgabe von ca. 109,1 Millionen Stammaktien (plus eine Super Voting Preferred Aktie) an die Verkäufer von Streamex. Bei Zustimmung würden die Streamex-Inhaber letztlich 75 % des vollständig verwässerten Eigenkapitals von BioSig kontrollieren; bestehende Investoren sinken auf 25 %.
  • Vorschlag 2: Autorisierung der Aktien, die den wandelbaren Schuldverschreibungen an YA II PN, Ltd. zugrunde liegen.
  • Vorschlag 3: Hinzufügung von 10.359.211 Aktien zum LTIP 2023 (insgesamt 14.735.806).
  • Vorschlag 4: Erlaubnis zur Ausgabe von ≥19,99 % der ausstehenden Aktien im Rahmen einer Standby Equity Purchase Agreement (SEPA) mit Yorkville.
  • Vorschlag 5: Erhöhung der genehmigten Stammaktien von 200 Millionen auf 500 Millionen.
  • Vorschlag 6: Staffelung des Vorstands in drei Klassen.

Der Vorstand empfiehlt einstimmig, allen Vorschlägen „ZUSTIMMEN“ zu stimmen. Das Quorum beträgt ein Drittel der Stimmrechte; die meisten Punkte erfordern eine einfache Mehrheit der abgegebenen Stimmen, aber für den gestaffelten Vorstand ist eine Mehrheit aller ausstehenden Aktien notwendig. Die Risikoaufklärung weist auf erhebliche Verwässerung, regulatorische Unsicherheiten bezüglich des Gold-Tokenisierungsmodells von Streamex und Integrationsherausforderungen hin. Das Stichtags- und Versammlungsdatum stehen noch aus und hängen von der Freigabe der SEC ab.

false 0001325670 0001325670 2025-07-24 2025-07-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

 

 

Form 8-K

 

 

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): July 24, 2025

 

Primis Financial Corp.

(Exact Name of Registrant as Specified in its Charter)

 

Virginia 001-33037 20-1417448
(State or Other Jurisdiction of
Incorporation)
(Commission File Number) (I.R.S. Employer Identification
Number)

 

1676 International Drive, Suite 900, McLean, Virginia 22102

(Address of Principal Executive Offices) (Zip Code)

 

(703) 893-7400

(Registrant's telephone number, including area code)

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
COMMON STOCK   FRST   NASDAQ

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

Item 2.02. Results of Operations and Financial Condition.

 

On July 24, 2025, Primis Financial Corp. (“Primis” or the “Company”) issued a press release announcing its financial results for the period ended June 30, 2025.  A copy of the press release is furnished and attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

 

Item 7.01. Regulation FD Disclosure.

 

The Company has prepared presentation materials (the “Investor Presentation”) that management intends to use from time to time hereafter in presentations about the Company’s operations and performance. The Company may use the Investor Presentation, possibly with modifications, in presentations to current and potential investors, analysts, lenders, business partners, acquisition candidates, customers, employees and others with an interest in the Company and its business.

 

A copy of the Investor Presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K and incorporated herein by reference. The Investor Presentation is also available on the Company's website at www.primisbank.com. Materials on the Company’s website are not part of or incorporated by reference into this report.

 

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibits 99.1 and 99.2 attached hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

 

Item 8.01. Other Events.

 

On July 24, 2025, Primis issued a press release announcing the declaration of a dividend payable on August 22, 2025 to shareholders of record as of August 8, 2025. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

99.1 Press Release dated July 24, 2025

 

99.2 Primis Financial Corp. Second Quarter 2025 Investor Presentation

 

104 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Primis Financial Corp.
     
     
Date: July 24, 2025 By:  /s/ Matthew A. Switzer
    Matthew A. Switzer
    Chief Financial Officer

 

 

 

FAQ

Why is BioSig (BSGM) issuing 109 million shares?

Those shares, plus one Super Voting Preferred share, constitute the purchase consideration for Streamex under Proposal 1.

How much will existing BSGM shareholders be diluted if all proposals pass?

Legacy holders drop to about 25% ownership; Streamex sellers capture roughly 75% of fully-diluted equity.

What change is proposed for BioSig’s authorized share count?

Proposal 5 seeks to raise the cap from 200 million to 500 million common shares.

What is the purpose of the SEPA with Yorkville?

Proposal 4 allows BioSig to sell up to 19.99% of outstanding stock to Yorkville as a standby equity source.

How will the board structure change?

Proposal 6 classifies directors into three staggered classes, each serving three-year terms, making board turnover more gradual.

Does the filing discuss specific financial results or earnings?

No; the preliminary proxy focuses on share issuances, governance changes and risk factors, not current earnings performance.
Primis Financial Corp

NASDAQ:FRST

FRST Rankings

FRST Latest News

FRST Latest SEC Filings

FRST Stock Data

299.15M
20.78M
3.61%
86.86%
0.32%
Banks - Regional
State Commercial Banks
Link
United States
MCLEAN